BioSpace News Archive

AstraZeneca’s Diabetes Drug Farxiga Decreases Heart Failure Risk

AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.

August 20, 2019

·

2 min read

·

Mark Terry

Report: Prices for Branded Drugs Continue to Increase, but at Slower Pace

Despite all the rhetoric and political saber-rattling, the price of branded drugs has still increased, although not as significantly.

August 20, 2019

·

2 min read

·

Alex Keown

Genetown

Synlogic Scraps Early-Stage Asset Following Interim Analysis

Synlogic said it opted to discontinue development of SYNB1020 following an interim analysis of Phase Ib/IIa data in 23 patients with cirrhosis and elevated blood ammonia.

August 20, 2019

·

2 min read

·

Alex Keown

FDA

First Antibiotic With New Mechanisms of Action Approved in Almost 20 Years

The U.S. FDA gave Nabriva Therapeutics a thumbs-up for both its oral and intravenous formulations of Xenleta (lefamulin) to treat community-acquired bacterial pneumonia in adults.

August 20, 2019

·

3 min read

·

Mark Terry

Business

Roche’s CMO to Retire, Eli Lilly’s Garraway to Fill Her Shoes

Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.

August 20, 2019

·

2 min read

·

Alex Keown

Business

Caris Life Sciences Expanding Footprint in Dallas-Fort Worth Area, Creating 500 New Jobs

Part of the new corporate park will be used to expand the company’s blood-based diagnostic tests in addition to blood-based molecular profiling and increasing research and development capacity.

August 20, 2019

·

2 min read

·

Mark Terry

Business

Merck, ASCO and Transformation: An Interview with Merck’s Scot Ebbinghaus

Scot Ebbinghaus, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories, took time out ahead of the meeting to discuss three of the company’s clinical trials being presented and the implications for oncology patients and Merck.

August 20, 2019

·

5 min read

·

Mark Terry

Biotech Beach

UCLA Researchers ID an Age-Damaged Subset of Amyloid in Alzheimer’s Patients

Researchers at the University of California, Los Angeles have identified a subclass of beta-amyloid that appears to be damaged by age and that appears to cause more damage in the brains of Alzheimer’s patients than so-called normal amyloid.

August 20, 2019

·

2 min read

·

Mark Terry

Business

Oncopeptides Appoints Klaas Bakker as New Chief Medical Officer

Oncopeptides AB announces that Klaas Bakker has been appointed as the new Chief Medical Officer for Oncopeptides, starting in November.

August 20, 2019

·

2 min read

Bio NC